tetano
Editor, Senior Moderator
Ann Vasc Dis
. 2023 Mar 25;16(1):31-37.
doi: 10.3400/avd.oa.22-00071.
Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study
Sen Yachi[SUP] 1 [/SUP], Makoto Takeyama[SUP] 1 [/SUP], Yuji Nishimoto[SUP] 2 [/SUP], Ichizo Tsujino[SUP] 3 [/SUP], Junichi Nakamura[SUP] 3 [/SUP], Naoto Yamamoto[SUP] 4 [/SUP], Hiroko Nakata[SUP] 5 [/SUP], Satoshi Ikeda[SUP] 6 [/SUP], Michihisa Umetsu[SUP] 7 [/SUP], Shizu Aikawa[SUP] 8 [/SUP], Hiroya Hayashi[SUP] 9 [/SUP], Hirono Satokawa[SUP] 10 [/SUP], Yoshinori Okuno[SUP] 11 [/SUP], Eriko Iwata[SUP] 12 [/SUP], Yoshito Ogihara[SUP] 13 [/SUP], Nobutaka Ikeda[SUP] 14 [/SUP], Akane Kondo[SUP] 15 [/SUP], Takehisa Iwai[SUP] 16 [/SUP], Norikazu Yamada[SUP] 17 [/SUP], Tomohiro Ogawa[SUP] 18 [/SUP], Takao Kobayashi[SUP] 4 [/SUP], Makoto Mo[SUP] 19 [/SUP], Yugo Yamashita[SUP] 11 [/SUP], On Behalf Of The Clot-Covid Study Investigators[SUP] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 [/SUP]
Affiliations
Abstract
Objectives: The relationship between the thrombotic event and prognosis in patients with coronavirus disease 2019 (COVID-19) has not yet been fully investigated in Japan. Our study aimed to investigate the clinical outcomes and risk factors for thrombosis in hospitalized patients with COVID-19 in Japan. Materials and Methods: We compared the patient characteristics and clinical outcomes among patients with thrombosis (N=55) and those without thrombosis (N=2839) by using a large-scale data of CLOT-COVID study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800). Thrombosis included venous thromboembolism, ischemic stroke, myocardial infarction, and systemic arterial thromboembolism. Results: Higher rates of mortality and bleeding events were shown in hospitalized patients with COVID-19 with thrombosis compared to those without thrombosis (all-cause mortality, 23.6% vs. 5.1%, P<0.001; major bleeding, 23.6% vs. 1.6%, P<0.001). Multivariable analysis revealed that the independent risk factors of thrombosis were male sex, D-dimer level on admission>1.0 µg/mL, and moderate and severe COVID-19 status on admission. Conclusions: The development of thrombosis in hospitalized patients with COVID-19 was related to higher mortality and major bleeding, and several independent risk factors for thrombosis could help determine the patient-appropriate treatment for COVID-19.
Keywords: COVID-19; clinical outcomes; risk factors; thrombosis.
. 2023 Mar 25;16(1):31-37.
doi: 10.3400/avd.oa.22-00071.
Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study
Sen Yachi[SUP] 1 [/SUP], Makoto Takeyama[SUP] 1 [/SUP], Yuji Nishimoto[SUP] 2 [/SUP], Ichizo Tsujino[SUP] 3 [/SUP], Junichi Nakamura[SUP] 3 [/SUP], Naoto Yamamoto[SUP] 4 [/SUP], Hiroko Nakata[SUP] 5 [/SUP], Satoshi Ikeda[SUP] 6 [/SUP], Michihisa Umetsu[SUP] 7 [/SUP], Shizu Aikawa[SUP] 8 [/SUP], Hiroya Hayashi[SUP] 9 [/SUP], Hirono Satokawa[SUP] 10 [/SUP], Yoshinori Okuno[SUP] 11 [/SUP], Eriko Iwata[SUP] 12 [/SUP], Yoshito Ogihara[SUP] 13 [/SUP], Nobutaka Ikeda[SUP] 14 [/SUP], Akane Kondo[SUP] 15 [/SUP], Takehisa Iwai[SUP] 16 [/SUP], Norikazu Yamada[SUP] 17 [/SUP], Tomohiro Ogawa[SUP] 18 [/SUP], Takao Kobayashi[SUP] 4 [/SUP], Makoto Mo[SUP] 19 [/SUP], Yugo Yamashita[SUP] 11 [/SUP], On Behalf Of The Clot-Covid Study Investigators[SUP] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 [/SUP]
Affiliations
- PMID: 37006864
- PMCID: PMC10064299
- DOI: 10.3400/avd.oa.22-00071
Abstract
Objectives: The relationship between the thrombotic event and prognosis in patients with coronavirus disease 2019 (COVID-19) has not yet been fully investigated in Japan. Our study aimed to investigate the clinical outcomes and risk factors for thrombosis in hospitalized patients with COVID-19 in Japan. Materials and Methods: We compared the patient characteristics and clinical outcomes among patients with thrombosis (N=55) and those without thrombosis (N=2839) by using a large-scale data of CLOT-COVID study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800). Thrombosis included venous thromboembolism, ischemic stroke, myocardial infarction, and systemic arterial thromboembolism. Results: Higher rates of mortality and bleeding events were shown in hospitalized patients with COVID-19 with thrombosis compared to those without thrombosis (all-cause mortality, 23.6% vs. 5.1%, P<0.001; major bleeding, 23.6% vs. 1.6%, P<0.001). Multivariable analysis revealed that the independent risk factors of thrombosis were male sex, D-dimer level on admission>1.0 µg/mL, and moderate and severe COVID-19 status on admission. Conclusions: The development of thrombosis in hospitalized patients with COVID-19 was related to higher mortality and major bleeding, and several independent risk factors for thrombosis could help determine the patient-appropriate treatment for COVID-19.
Keywords: COVID-19; clinical outcomes; risk factors; thrombosis.